Cisplatin (CDDP): Gold-Standard DNA Crosslinking Agent for Cancer Research

Executive Summary: Cisplatin (CAS 15663-27-1) is a platinum-based chemotherapeutic compound widely used in cancer research due to its ability to induce DNA crosslinks and trigger apoptosis via caspase and p53 pathways (Zhang et al. 2025). Its mechanism involves forming intra- and inter-strand crosslinks at guanine bases, blocking DNA replication and transcription. Cisplatin also increases reactive oxygen species (ROS), promoting oxidative stress and apoptosis. In xenograft models, intravenous administration at 5 mg/kg on days 0 and 7 significantly inhibits tumor growth (APExBIO). Resistance mechanisms, including metabolic reprogramming and post-translational modifications, are active areas of study. Cisplatin remains essential in studies on chemotherapy resistance and apoptosis induction.

Biological Rationale

Cisplatin (CDDP) is a platinum-based DNA crosslinking agent for cancer research. Its primary use is in chemotherapy studies, where it serves as a reference compound for investigating DNA damage response and apoptosis mechanisms. Cisplatin targets highly proliferative cells by interfering with DNA structure and function. It is especially relevant in research on ovarian, lung, and head and neck squamous cell carcinoma (Nature Communications 2025). The clinical relevance of cisplatin is underscored by its inclusion as first-line therapy—often in combination with gemcitabine—in advanced cholangiocarcinoma, despite challenges posed by drug resistance (Zhang et al. 2025).

Mechanism of Action of Cisplatin

Cisplatin exerts cytotoxicity primarily through covalent binding to DNA at N7 positions of guanine bases. This forms intrastrand (∼90%) and interstrand (∼5–10%) crosslinks, which distort the DNA helix and block polymerase progression (APExBIO). Blockade of replication and transcription triggers cell cycle arrest and apoptosis. The DNA damage response activates p53, which in turn initiates intrinsic apoptosis via caspase-9 and caspase-3 (ECL Chemiluminescent). Additionally, cisplatin increases intracellular ROS, causing oxidative stress and activating ERK-dependent apoptotic signaling. This multifaceted mechanism underpins its utility in apoptosis assays and chemoresistance studies.

Evidence & Benchmarks

• Cisplatin forms DNA crosslinks at guanine N7, blocking replication and transcription (APExBIO).
• Induces p53- and caspase-dependent apoptosis in a wide range of tumor cell lines (ECL Chemiluminescent).
• Triggers ERK-mediated apoptosis through ROS generation and lipid peroxidation (APExBIO).
• Inhibits tumor growth in vivo: intravenous injection at 5 mg/kg on days 0 and 7 significantly suppresses xenograft progression (Zhang et al. 2025).
• Resistance mechanisms include metabolic reprogramming, notably via PDHA1 succinylation, which modulates sensitivity to cisplatin and gemcitabine (Nature Communications 2025).
• Widely used for benchmarking apoptosis assays and DNA damage response workflows (Angiotensin-1-2-1-8-Amide).

This article clarifies the molecular mechanisms and practical benchmarks beyond the mechanistic overview provided in this recent summary.

Applications, Limits & Misconceptions

Cisplatin is used in cell-based assays, animal xenograft models, and mechanistic studies on apoptosis, chemoresistance, and DNA repair. Its robust, verifiable effects make it a reference agent for apoptosis and DNA-damage assays (Pyrophosphatase-Inorganic). The A8321 kit from APExBIO is optimized for experimental reproducibility in oncology workflows. However, efficacy is context-dependent and resistance can arise via metabolic or DNA repair pathway alterations.

Common Pitfalls or Misconceptions

• Cisplatin is not universally effective—many solid tumors develop resistance through enhanced DNA repair or altered metabolism (Zhang et al. 2025).
• It is insoluble in water and ethanol; improper solvent use (e.g., DMSO) can inactivate the compound (APExBIO).
• Solutions are chemically unstable—fresh preparation is mandatory for consistency.
• ROS-mediated toxicity may confound results in non-cancerous models.
• Does not induce apoptosis in cells lacking functional p53 or caspase activity (ECL Chemiluminescent).

Workflow Integration & Parameters

For optimal workflow integration, Cisplatin (A8321) is supplied as a powder for maximum stability. Store at room temperature, protected from light. Solutions should be freshly prepared in DMF at concentrations ≥12.5 mg/mL; avoid DMSO due to risk of inactivation. Warming and ultrasonic treatment enhance solubility. For in vivo xenograft assays, administer intravenously at 5 mg/kg on days 0 and 7. Benchmark assays include apoptosis (caspase-3/9), ROS quantification, and DNA damage markers (γH2AX). For detailed experimental guidance and troubleshooting, see this translational oncology workflow article, which this article extends by mapping new mechanisms of chemoresistance and metabolic adaptation.

Conclusion & Outlook

Cisplatin remains the benchmark DNA crosslinking agent for cancer research, enabling precise study of apoptosis, DNA repair, and chemoresistance. Advances in understanding metabolic resistance, such as PDHA1 succinylation and α-KG accumulation, open new avenues for combinatorial strategies and sensitization (Zhang et al. 2025). Continued integration of APExBIO reagents and mechanistic workflows will drive innovation in translational oncology. This article updates prior summaries (e.g., Cisplatin: Gold-Standard DNA Crosslinking Agent) by incorporating the latest evidence on metabolic resistance and workflow optimization.